What is Amlodipine (calcium channel blocker)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Amlodipine?

Amlodipine is a long-acting dihydropyridine calcium channel blocker that inhibits calcium ion influx into vascular smooth muscle, producing pronounced peripheral arterial vasodilation with minimal effects on cardiac conduction or contractility. 1

Mechanism of Action

Amlodipine works by blocking L-type calcium channels in vascular smooth muscle cells, preventing the transmembrane influx of calcium ions required for muscle contraction. 1 This selective inhibition has a greater effect on vascular smooth muscle than on cardiac muscle, distinguishing it from non-dihydropyridine calcium channel blockers. 1

The drug binds to both dihydropyridine and nondihydropyridine binding sites with a gradual rate of association and dissociation, resulting in a gradual onset of effect rather than rapid vasodilation. 1 This pharmacological profile minimizes reflex tachycardia and reduces the incidence of side effects like headache that are common with shorter-acting calcium antagonists. 2

Pharmacological Properties

Amlodipine produces the most marked peripheral arterial vasodilation among calcium channel blockers, with minimal effects on atrioventricular node function, sinus node function, or cardiac conduction. 3, 4

Key pharmacokinetic characteristics include:

  • Elimination half-life of 36-60 hours, allowing true once-daily dosing with sustained 24-hour blood pressure control. 5, 6
  • High oral bioavailability of 60-80% with slow absorption, reaching peak plasma concentrations 6-8 hours after dosing. 6
  • Minimal fluctuation (20-25%) in plasma drug concentration between doses during once-daily administration. 6
  • Gradual onset and offset of action, with blood pressure slowly returning to baseline over 7-10 days after discontinuation without rebound effect. 6

Clinical Indications

Amlodipine is FDA-approved for three primary indications: 1

Hypertension

Amlodipine relaxes blood vessels, allowing blood to flow more easily and lowering blood pressure through reduction in peripheral vascular resistance. 1 The American Heart Association identifies amlodipine as having the strongest evidence among calcium channel blockers for hypertension management, demonstrating equivalent or superior outcomes compared to other antihypertensive classes in major cardiovascular outcome trials. 7

Chronic Stable Angina (Exertional Angina)

Amlodipine reduces total peripheral resistance (afterload) and the rate-pressure product, thereby decreasing myocardial oxygen demand at any given level of exercise. 1 The drug provides effective 24-hour anti-anginal and anti-ischemic efficacy when dosed once daily. 2

Vasospastic Angina (Prinzmetal's or Variant Angina)

Amlodipine blocks constriction and restores blood flow in coronary arteries and arterioles in response to calcium, potassium, epinephrine, serotonin, and thromboxane A2. 1 The European Society of Cardiology identifies calcium channel blockers as the treatment of choice for vasospastic angina, with amlodipine blocking coronary artery constriction effectively. 7

Dosing

Standard dosing begins at 5 mg once daily, which can be increased to 10 mg once daily if needed to control symptoms. 1, 2 The medication can be taken with or without food, and timing consistency (such as with breakfast, dinner, or bedtime) improves adherence. 1

Clinical Advantages

Amlodipine demonstrated equivalent cardiovascular outcomes to thiazide diuretics and ACE inhibitors in the ALLHAT trial, with no significant differences in fatal coronary heart disease, nonfatal myocardial infarction, combined coronary outcomes, or all-cause mortality. 7

In the CAMELOT study, amlodipine treatment in patients with stable coronary artery disease and normal blood pressure tended to reduce the incidence of hard endpoints, though results were not statistically significant. 3

Important Clinical Considerations

Heart Failure Patients

Amlodipine should not be used as routine treatment in patients with heart failure with reduced ejection fraction (HFrEF), though it may be considered for concurrent hypertension or angina as it has neutral effects on morbidity and mortality. 4, 7 The American College of Cardiology recommends close monitoring for signs of worsening heart failure, including increased dyspnea, weight gain, or edema in patients taking amlodipine. 4

Combination Therapy

Amlodipine combines effectively with ACE inhibitors or ARBs, reducing edema and improving blood pressure control through complementary mechanisms. 7 When combining with beta-blockers, long-acting dihydropyridines like amlodipine are preferred over non-dihydropyridines to avoid excessive bradycardia or heart block. 7

Amlodipine should never be combined with non-dihydropyridine calcium channel blockers (diltiazem, verapamil) in heart failure patients, as these agents cause myocardial depression. 4

Drug Interactions

NSAIDs should be avoided in patients taking amlodipine for hypertension, as they worsen blood pressure control and may precipitate heart failure. 4

Common Adverse Effects

The most common adverse effect is peripheral edema (swelling of legs or ankles). 1, 5 Other side effects include:

  • Tiredness or extreme sleepiness 1
  • Dizziness 1
  • Flushing (hot or warm feeling in face) 1
  • Headache 5

Amlodipine does not cause postural hypotension, reflex tachycardia, or cardiac conduction disturbances due to its gradual onset of action. 8, 6

Critical Safety Warning

Rarely, when first starting amlodipine or increasing the dose, patients may experience a heart attack or worsening angina. 1 If this occurs, immediate medical attention is required—either call a doctor right away or go directly to a hospital emergency room. 1

In cases of amlodipine overdose, calcium administration, vasopressors, and high-dose insulin therapy may be required for severe toxicity. 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Amlodipine Pharmacology and Clinical Considerations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Amlodipine: a new calcium antagonist.

American journal of hospital pharmacy, 1994

Guideline

Calcium Channel Blockers for Hypertension and Angina Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.